IP Library › Patent Application 15232222
Patent Application
App. No. 15/232,222

PROTEIN KINASE INHIBITORS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/232,222
Abstract

A compound of formula (I), wherein R 3 , R 4 , G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Claims (33)

1 - 18 . (canceled)

19 . A method for the treatment of cancer comprising administering an effective amount of a compound of formula (I)

wherein

is CH or N;

G is a group of formula

wherein ring A is a phenyl ring or a 5-12 membered heterocyclic ring, and

R 1 is H, C 1-7 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-7 alkyl, C 1-7 alkoxy, C 1-7 alkyl carbonyl, amino, hydroxy, hydroxy C 1-7 alkyl, C 1-7 alkylamino C 1-7 alkyl, phenyl C 1-7 alkoxy, —NHC(O)—R 21 , —R 12 —C(O)—R 13 , —SO 2 —R 14 or -E-R 6 , and

R 2 is H, halogen, C 1-7 alkyl or oxo;

ring B is a 5-12 membered carbocyclic or heterocyclic ring;

R 3 is H, halogen, C 1-7 alkyl, C 1-7 alkoxy, cyano or an optionally substituted 5-6 membered heterocyclic ring;

R 4 is H, halogen, C 1-7 alkyl or oxo;

M is —NHR 5 ;

R 5 is H, —C(O)R 7 , —SO 2 R 8 , —C(O)-D-R 9 or an optionally substituted 5-6 membered heterocyclic ring;

R 6 is an optionally substituted 5-6 membered heterocyclic ring;

R 7 is C 1-7 alkyl, C 2-7 alkenyl, C 3-7 cycloalkyl, C 1-7 alkoxy, C 1-7 alkoxy C 1-7 alkyl, carboxy C 1-7 alkyl, C 1-7 alkoxy carbonyl C 1-7 alkyl, C 1-7 alkylamino C 1-7 alkyl, —NH—R 10 or —NH—X 1 —R 11 ;

R 8 is C 1-7 alkyl, C 2-7 alkenyl, C 3-7 cycloalkyl, hydroxy C 1-7 alkyl, —NR 18 R 19 , —NH—X 2 —R 20 , phenyl or an optionally substituted 5-6 membered heterocyclic ring;

R 9 is phenyl or an optionally substituted 5-6 membered heterocyclic ring;

R 10 is C 1-7 alkyl or C 3-7 cycloalkyl;

R 11 is phenyl or an optionally substituted 5-6 membered heterocyclic ring;

R 12 and R 21 are C 1-7 alkyl;

R 13 is C 1-7 alkoxy, amino or hydroxy;

R 14 is C 1-7 alkyl or C 3-7 cycloalkyl;

R 18 and R 19 are, independently, H, C 1-7 alkyl or C 3-7 cycloalkyl;

R 20 is phenyl or an optionally substituted 5-6 membered heterocyclic ring;

E is a bond or a C 1-7 alkyl;

D is a bond or a C 1-7 alkyl;

X 1 and X 2 are, independently, a bond or C 1-7 alkyl;

or a pharmaceutically acceptable salt thereof to a patient in need thereof.

20 . The method according to claim 19 , wherein the cancer is multiple myeloma.

21 . The method according to claim 19 , wherein the cancer is gastric cancer.

22 . The method according to claim 19 , wherein the cancer is endometrial cancer.

23 . The method according to claim 19 , wherein the cancer is prostate cancer.

24 . The method according to claim 19 , wherein the cancer is breast cancer.